Claudio Jommi

Claudio Jommi is Affiliate Professor of Health Policy at SDA Bocconi School of Management - Government, Health and Not for Profit Knowledge Group.

He is also Member of the Executive Committee, Director of the Health Policy Area and Scientific Coordinator of the Pharmaceutical Observatory at Cergas (Centre for Research on Health and Social Care Management), SDA Bocconi.He is Director of the Master of International Health Care Management Economics and Policy (MIHMEP). He has been a visiting professor at Essec Business School, Cergy (Paris), at the Herivan K. Haub School of Business, St Joseph University, Philadelphia (US), at the Andrija School of Public Health, Zagreb and the University of Claude Bernard Lyon 1 (European Market Access University Diploma) (Paris).He was the President of the Italian Health Economics Association (2014-2017).

His research activity is focused on Market Access for Medicines and other Medical Technologies, Pharmaceutical Economics, Policy and Management, Health Technology Assessment and Decision Making in Health Care.

He has had his work published in many international and national journals, including BMJ Open, Drug Design Development and Therapy, Frontiers in Pharmacology, European Journal of Health Economics, Health Policy, International Journal of Health Planning and Management, Journal of Medical Marketing, Pharmacoeconomics, PLOS and PLOS Neglected Diseases, Public Money and Management, Social Science and Medicine, Value in Health.

Teaching domains

• Pharmaceutical and Other Medical Technologies Markets
• Policy Impact Analysis
• Comparative Health Care Systems

Latest publications

• FINCH A. P., MEREGAGLIA M., CIANI O., ROUDIJK B., JOMMI C.
  An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration
  Social Science & Medicine, 2022, vol.292
  
• RONCO V., DILECCE M., LANATI E., CANONICO P. L., JOMMI C.
  Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
  Journal of Pharmaceutical Policy and Practice, 2021, vol.14, no. 1, pp.30
  
• JOMMI C., LISTORTI E., VILLA F., GHISLANDI S., GENAZZANI A., CANGINI A., TROTTA F.
  Variables affecting pricing of orphan drugs: the Italian case
  Orphanet Journal of Rare Diseases, 2021, vol.16, no. 1, pp.1-10
  
• ARDITO V., CIANI O., FEDERICI C. B., FURNARI A., FINCH A., JOMMI C., MALANDRINI F., MEREGAGLIA M., TARRICONE R.
  Esiti di salute e performance del Servizio Sanitario Nazionale in Rapporto OASI 2021
  Cergas (Eds),Egea, chap. 7, pp.303-359, 2021
  
• ROGNONI C., BERTOLANI A., JOMMI C.
  Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects
  Clinical Drug Investigation, 2021, vol.41, no. 4, pp.303-319
  
• JOMMI C., GALEONE C., BRUZZI P.
  Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system
  BMJ, 2021, vol.11, no. 1, pp.e041259
  

Grants & Honors

• Management of funds for innovative medicines - MSD Oncology , 2020
• Valuation of the EQ-5D-5L in Italy - EuroQol Research Foundation , 2019